Polyclonal serum free light chains: A biomarker of disease prognosis or of immune senescence?

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 3033-3034

  Bibas, Michele ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALLERGIC PNEUMONITIS; ASTHMA; ATOPY; B LYMPHOCYTE ACTIVATION; DENDRITIC CELL; DERMATITIS; FIBROSING ALVEOLITIS; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; LETTER; LIGHT CHAIN; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POLYCLONAL SERUM FREE LIGHT CHAIN; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SENESCENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MYELODYSPLASTIC SYNDROMES; NEPHELOMETRY AND TURBIDIMETRY; PRIMARY MYELOFIBROSIS;

EID: 84865211553     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.4043     Document Type: Letter

References (13)

1. Pardanani A, Lasho TL, Finke CM, et al: Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 30:1087-1094, 2012
2. Hutchison CA, Landgren O: Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 57:1387-1389, 2011
3. Bradwell AR: Serum Free Light Chain Analysis (plus Hevylite; ed 6). San Diego, CA, The Binding Site, 2010, pp 10-17
4. Maurer MJ, Micallef IN, Cerhan JR, et al: Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 29:1620-1626, 2011
5. Thompson CA, Maurer MJ, Cerhan JR, et al: Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol 86:998-1000, 2011
6. Morabito F, De Filippi R, Laurenti L, et al: The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 118:6353-6361, 2011
7. Tsai HT, Caporaso NE, Kyle RA, et al: Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: A prospective study. Blood 114:4928-4932, 2009
8. Landgren O, Goedert JJ, Rabkin CS, et al: Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28:773-779, 2010
9. Bibas M, Trotta MP, Cozzi-Lepri A, et al: Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol [epub ahead of print on April 26, 2012]
10. Nakano T, Matsui M, Inoue I, et al: Free immunoglobulin light chain: Its biology and implications in diseases. Clin Chim Acta 412:843-849, 2011
11. Thio M: Immunoglobulin free light chains: New insights in mast cell activation and immunology [doctoral thesis]. Utrecht University, Utrecht, the Netherlands, 2011
12. Dispenzieri A, Katzmann JA, Kyle RA, et al: Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 87:517-523, 2012
13. Zitvogel L, Kepp O, Galluzzi L, et al: Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13:343-351, 2012